Robert E. Funck Jr. - Feb 18, 2022 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role: EXECUTIVE VICE PRESIDENT
Signature: /s/ Robert E. Funck, Jr. by Jessica H. Paik, Attorney-in-Fact
Stock symbol: ABT
Transactions as of: Feb 18, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/23/2022, 07:12 PM
Next filing: Mar 2, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABT	Common shares without par value	Award	$0	+28.7K	+15.2%	$0.00	217K	Feb 18, 2022	Direct	F1
holding	ABT	Common shares without par value						10K	Feb 18, 2022	By Trust	F2
holding	ABT	Common shares without par value						10K	Feb 18, 2022	By Trust	F2
holding	ABT	Common shares without par value						18.1K	Feb 18, 2022	Profit Sharing Trust	F3
holding	ABT	Common shares without par value						500	Feb 18, 2022	By Daughter	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABT	Option (right to buy)	Award	$0	+134K		$0.00	134K	Feb 18, 2022	Common Shares	134K	$117.58	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2	Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust.
F3	Balance in the Abbott Laboratories Stock Retirement Trust as of February 18, 2022.
F4	The reporting person disclaims beneficial ownership of all securities held by his daughter.
F5	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 44,556 on February 18, 2023, 44,557 on February 18, 2024, and 44,557 on February 18, 2025.